摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-benzyl-4-methyl-2H-pyran-2-one | 14983-32-5

中文名称
——
中文别名
——
英文名称
6-benzyl-4-methyl-2H-pyran-2-one
英文别名
Streptpyrone A;6-benzyl-4-methylpyran-2-one
6-benzyl-4-methyl-2H-pyran-2-one化学式
CAS
14983-32-5
化学式
C13H12O2
mdl
——
分子量
200.237
InChiKey
WFYCCNGMMNQOLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    367.3±21.0 °C(Predicted)
  • 密度:
    1.145±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-benzyl-4-methyl-2H-pyran-2-one吡啶tetraphosphorus decasulfide一水合肼 作用下, 以 为溶剂, 反应 17.0h, 生成 1-Amino-6-benzyl-4-methylpyridin-2-one
    参考文献:
    名称:
    抑制癌症相关突变异柠檬酸脱氢酶:合成、结构-活性关系和选择性抗肿瘤活性
    摘要:
    异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症,例如神经胶质瘤。与野生型 (WT) IDH1 不同,突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG),从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物,并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM,而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关,R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障,并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性(EC 50 = 0.26–1.8 μM)。
    DOI:
    10.1021/jm500660f
  • 作为产物:
    描述:
    硫酸溶剂黄146 作用下, 反应 5.0h, 以75%的产率得到6-benzyl-4-methyl-2H-pyran-2-one
    参考文献:
    名称:
    抑制癌症相关突变异柠檬酸脱氢酶:合成、结构-活性关系和选择性抗肿瘤活性
    摘要:
    异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症,例如神经胶质瘤。与野生型 (WT) IDH1 不同,突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG),从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物,并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM,而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关,R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障,并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性(EC 50 = 0.26–1.8 μM)。
    DOI:
    10.1021/jm500660f
点击查看最新优质反应信息

文献信息

  • Environmentally Sustainable and Chemo-selectively Favorable Synthesis of Substituted 2<i>H</i>-Pyran-2-ones in Water under MWI
    作者:Liang-Yan Cui、Xin Wang、Yan He、Xue-Sen Fan
    DOI:10.1002/jccs.201300013
    日期:2014.2
    this paper, a novel synthesis of diversely substituted 2H‐pyran‐2‐ones via the tandem reaction of 3‐hydroxyhexa‐4,5‐allenic esters in water under the promotion of MWI has been developed. Compared with those reactions carried out in organic solvents, water mediated synthesis of poly‐substituted 2H‐pyran‐2‐ones is not only environmentally sustainable, but also chemo‐selectively favorable.
    在本文中,在MWI的促进下,通过3-羟基六-4-5,5-烯丙酸酯在水中的串联反应,开发了一种新型的2 H-吡喃-2-酮的合成方法。与在有机溶剂中进行的反应相比,水介导的多取代2 H-吡喃-2-酮的合成不仅对环境可持续,而且对化学选择性也有利。
  • Tandem reaction of 3-hydroxyhexa-4,5-allenic esters: a novel access to diversely substituted 2H-pyran-2-ones and indenes
    作者:Haiyun Xu、Xinying Zhang、Yan He、Shenghai Guo、Xuesen Fan
    DOI:10.1039/c2cc30247k
    日期:——
    A highly efficient synthesis of diversely substituted 2H-pyran-2-ones and indenes through Brønsted acid promoted tandem reaction of the readily obtainable 3-hydroxyhexa-4,5-allenic esters under extremely mild conditions has been developed.
    在极其温和的条件下,通过容易获得的 3-hydroxyhexa-4,5-allenic esters(3-羟基六-4,5-异烯酯)的布氏酸促进串联反应,开发出了一种高效合成多种取代的 2H-吡喃-2-酮和茚的方法。
  • Lohaus; Dittmar, Arzneimittel-Forschung/Drug Research, 1981, vol. 31, # 8 a, p. 1311 - 1316
    作者:Lohaus、Dittmar
    DOI:——
    日期:——
  • Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
    作者:Baisong Zheng、Yuan Yao、Zhen Liu、Lisheng Deng、Justin L. Anglin、Hong Jiang、B. V. Venkataram Prasad、Yongcheng Song
    DOI:10.1021/ml400036z
    日期:2013.6.13
    Mutations in isocitrate dehydrogenase (IDH), a key enzyme in the tricarboxylic acid cycle, have recently been found in similar to 75% glioma and similar to 20% acute myeloid leukemia. Different from the wild-type enzyme, mutant IDH1 catalyzes the reduction of alpha-ketoglutaric acid to D-2-hydroxyglutaric acid. Strong evidence has shown mutant IDH1 represents a novel target for this type of cancer. We found two 1-hydroxypyridin-2-one compounds that are potent inhibitors of R132H and R132C mutants with K-i values as low as 120 nM. These compounds exhibit >60-fold selectivity against wild-type IDH1 and can inhibit the production of D-2-hydroxyglutaric acid in IDH1 mutated cells, representing novel chemical Probes for cancer biology studies. We also report the first inhibitor-bound crystal structures of IDH1(R132H), showing these inhibitors have H-bond, electrostatic, and hydrophobic interactions with the mutant enzyme. Comparison with the substrate-bound IDH1 structures revealed the structural basis for the high enzyme selectivity of these compounds.
  • Development of Novel <i>N</i>-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents
    作者:Linghao Hu、Hongxuan Feng、Hongguang Zhang、Songda Yu、Qinyuan Zhao、Wei Wang、Fengxia Bao、Xun Ding、Jiajing Hu、Manjiong Wang、Yixiang Xu、Zengrui Wu、Xiaokang Li、Yun Tang、Fei Mao、Xiaoyan Chen、Haiyan Zhang、Jian Li
    DOI:10.1021/acs.jmedchem.9b01338
    日期:2020.2.13
    Our previous study had identified ciclopirox (CPX) as a promising lead compound for treatment of ischemic stroke. To find better neuroprotective agents, a series of N-hydroxypyridone derivatives based on CPX were designed, synthesized, and evaluated in this study. Among these derivatives, compound 11 exhibits significant neuroprotection against oxygen glucose deprivation and oxidative stress -induced injuries in neuronal cells. Moreover, compound 11 possesses good blood-brain barrier permeability and superior antioxidant capability. In addition, a complex of compound 11 with olamine-11.01a possesses good water solubility, negligible hERG inhibition, and superior metabolic stability. The in vivo experiment demonstrates that 11.01a significantly reduces brain infarction and alleviates neurological deficits in middle cerebral artery occlusion rats. Hence, compound 11.01a is identified in our research as a prospective prototype in the innovation of stroke treatment.
查看更多